



Angel E. Alsina, M.D., FACS, FAASLD PUBLICATIONS

Publications

Non-refereed journals:

1. **Alsina A**, Hull D, Bartus S, and Schweizer, R. Liver Transplantation for Acute Fulminant Hepatic Failure. *Connecticut Medicine*. 1992; 56: 235-239
2. **Alsina A**, Nagashima I, and Schweizer R. Orthotopic Porcine Small Bowel Transplantation with Low Dose Cyclosporine in Triple Immunosuppressive Therapy. *Transplantation Proceedings* 1992; 24: 1169-1173.
3. Nagashima I, Bergman L, **Alsina A**, and Schweizer R. Auxiliary Partial Liver Transplantation in Pigs with Acute Ischemic Liver Failure. *Transplantation Proceedings* 1993; 24(2): 1933-34.
4. Schweizer RT, **Alsina AE**, Rosson R, Bartus SA. Liver Transplantation for Metastatic Neuroendocrine Tumors. *Transplantation Proceedings* 1993; 24(2): 1933-4.
5. Kemmer N, **Alsina A**, Neff GW. Orthotopic liver transplantation in a multiethnic population: role of spatial accessibility. *Transplant Proc*. 2011;43(10):3780-2.
6. Kemmer N, **Alsina A**, Neff GW. Social determinants of orthotopic liver transplantation candidacy: role of patient-related factors. *Transplant Proc*. 2011; 43(10):3769-72.
7. **Alsina A**, Beharry A, Beharry N, Kemmer N, Franco E, Rojas H, Neff GW. Epidemiology of Hepatocellular Carcinoma in Florida – Part I: A Statewide Report. *Florida Public Health Review*, 2012; 9: 18-23
8. Ferro T, **Alsina A**, Rumbak M. Portopulmonary hypertension: An effect of vasomodulation and mortality post transplant. *Glob J Resp Care* 2014; 1:22-28.
9. A pilot study of high risk adjuvant sorafenib in high risk liver transplantation for hepatocellular carcinoma. **Alsina A**, Franco E, et al. *JSM Clin Oncol Res* 2016; 4:1049.

Refereed Journals:

1. **Alsina A**, Bartus S, Hull D, Rosson R, and Schweizer R: Liver Transplantation for Metastatic Neuroendocrine Tumor. *J. Clin Gastroenterol*. 1990; 12(5): 533-7.
2. **Alsina A**, Sziklas J, Rosenberg R, and Schweizer R: Value of 111-Indium Leukocyte Scans in Febrile Transplant
3. Savaria D, Townsend M, Alleman K, **Alsina A**, Olson N, Bartus S, Hull D, and Schweizer R. The

- Impact of Heart Donor and Recipient Cytomegalovirus Status on the Incidence of CMV Infection. *J Transplant Coordination* 1991; 1: 137-139.
4. Nagashima I, Bergman L, **Alsina AE**, Schweizer RT. Auxiliary heterotopic partial liver transplantation in pigs with acute ischemic liver failure. *Hepatogastroenterol* 1997;44:142631
 5. Torres E., Guzman A., Vazquez M., Gregory F., Lozano H., Rivera C., **Alsina A**. Improving access to Liver Transplantation: The University of Puerto Rico Experience. *PRHSJ* 2004; 2:183-8.
 6. **Alsina A.**, Huang J., Bowers V., Leone J., Gonzalez H., Antunez I., Torres E., Potter T. Outcome of Liver Transplantation in a Hispanic Population: 100 Liver Transplants in Puerto Ricans. *PRHSJ* 2009; 28:301-306
 7. **Alsina A**. Liver Transplantation for Hepatocellular Carcinoma. *Cancer Control* 2010; 17: 83-86
 8. Le TV, Rumbak M, Liu SS, **Alsina A**, Van Loveren H, Agazzi S. Insertion of Intracranial Pressure Monitors in Fulminant Hepatic Failure Patients: Early Experience Using Recombinant Factor VII. *Neurosurgery* 2010; 66: 455-458
 9. Toomey P, Golkar F, Hernandez J, Clark W, Luberic K, **Alsina A**, Rosemurgy A. Outcome after TIPS: A Bridge to Nowhere. *Am J Surg.* 2011 Nov;202(5):561-4. Epub 2011 Sep 23.
 10. Clark W, Golkar F, Toomet P, Paul H, Marcadis A, Okpaleke C, Vice M, Hernandez J, **Alsina A**, Rosemurgy AS. Uncovering the truth about covered stents: is there a difference between covered versus uncovered stents with transjugular intrahepatic portosystemic shunts? *Am J Surg.* 2011 202(5):561-4.
 11. Lawindy S, Kurian T, Kim T, Manfag R, Armstrong P, **Alsina A**, Sheffield C, Sexton W, Spiess P. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. *BJU Int.* 2012 Apr 30.
 12. Rivera, MN, Jowsey S, **Alsina A**, Torres EA. Barriers to Liver Transplant in Puerto Ricans With Chronic Liver Disease. *PRHSJ.* 2012; 4:199-204.
 13. Mathur A, Leone JP, Franco ES, Osman-Mohamed H, Rojas H, Kemmer N, Neff G, Rosemurgy AS, **Alsina AE**. Obesity Portends Increased Morbidity, Abbreviated Survival, and early recurrence Following Orthotopic Liver Transplantation for Hepatocellular Carcinoma. *HPB* 2013; 15: 504-10
 14. Neff G, **Alsina A**, Kemmer N, et al. Update on the management of cirrhosis - focus on cost effective preventative strategies. *ClinicoEconomics and Outcomes Research.* 2013;5: 143-152
 15. Trotter J, **Alsina A**, Grafals M. *Liver Transpl.* 2013;19(8):826-42. Early use of renal-sparing agents in liver transplantation: A closer look.
 16. **Alsina A**, Nakshabandi A, et al. Liver Transplantation for Hepatocellular Carcinoma in Puerto Ricans: Underutilization of a Curative Therapy. *PRHSJ.* 2014;33(4):170-6.
 17. Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, Cece E, **Alsina A**. Non-Alcoholic Fatty Liver Disease Epidemic and its Implications for Liver Transplantation. *Transplantation.* 2013 Nov 27;96(10):860-2

18. **Alsina A**, Nakshabandi A, Torres EA. Liver Transplantation for Hepatocellular Carcinoma in Puerto Ricans: Underutilization of a Curative Therapy. *P R Health Sci J*. 2014 Dec;33(4):170-6.
19. Naugler W, **Alsina A**, Frenette C, Rosssaro L, Sellers M. Building the Multidisciplinary Team for Management of Patients with Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2015 May;13(5):827-35
20. **Alsina A**, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, Kemmer N. Can sorafenib extends survival of recurrent hepatocellular carcinoma following liver transplantation? *American Surgeon* 2014;80(7):680-4.
21. Nakshabandi A, Franco E, Kemmer N, **Alsina A** Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma: A case report. *ACG Case Rep J*. 2016 Aug 17;3(4):e106
22. Liver transplantation recipient with malignant transformation of hepatic adenoma. Leone P, Santos M, Finan J, **Alsina A**, Franco S. *Case Reports of Clin Pathol*. 2016; 3: 8-14.
23. **Alsina A**, Athienitis A, et al. Outcomes of elective abdominal surgeries in cirrhotic patients performed by liver transplant surgeons. Are they safer? *Am J Surg*. 2018 Sep;216(3):518-523
24. **Alsina A**, Apple R, Kemmer R., Orłowski D. The malleability of transplant criteria: At what costs? *Narrative Inquiry in Bioethics* 2019.
25. **Alsina AE**, **Alsina AA**, Athienitis A, Buggs J, Aslam S, Kemmer N. Is Fulminant Hepatic Failure the Nemesis for Liver Transplant Centers? A Two Decade Psycho-Social and Long Term Outcomes Study. *American Surgeon* 2018. 1;84(7):1197-1203.
26. DA, Teperman L, Ueda K, Silverman A, Chapman W, **Alsina AE**, Tyler C, Stevens DR. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. *Clin Pharmacol Drug Dev*. 2019 Jan 22. doi: 10.1002/cpdd.657
27. **Alsina AE**, Kudo M, Vogel A, Cheng AL, Tak W, Ryoo B, Evans TR, Lopez C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn R. Subsequent systemic anticancer medication following first line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. *Liver Cancer* (# LIC-2019-9-19).